Taking stock of the drug industry, from the lab to the medicine chestFebruary 9, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Mariam Zuhaib/AP STAT+ | Senate panel passes drug patent reforms, but not without dissent A key Senate committee passed legislation to prevent drug companies from gaming the patent system to delay competition from cheaper generics. By John Wilkerson STAT+ | Cigarette, vape maker Reynolds American calls on the FDA to pull Puff Bar, Elf Bar, and other disposables off store shelves Cigarette giant Reynolds American is calling on the FDA to crack down on manufacturers of disposable e-cigarettes, like Puff Bar and Elf Bar. By Nicholas Florko STAT+ | How the CPAP crisis has paved the way for Philips' biggest rivals to rake in profits It could be difficult for Philips to regain its market share after sweeping CPAP recall — giving rivals like ResMed an advantage. By Lizzy Lawrence AP Photo/Ted S. Warren, File What people on Medicare can expect once the Covid-19 public health emergency ends People with Medicare will pay more for some Covid-19 tests and treatments after the public health emergency ends. By Rachel Cohrs In large study, a single antibiotic dose slashed rate of sepsis in childbirth An inexpensive antibiotic, azithromycin, could reduce a top cause of maternal deaths, sepsis, in low- and middle-income countries. By Helen Branswell More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments